earnings
confidence high
sentiment neutral
materiality 0.75
Regeneron Q1 revenue up 17% to $2.97B; non-GAAP EPS $11.49, GAAP EPS $8.61; Dupixent +43%
REGENERON PHARMACEUTICALS, INC.
2022-Q1 EPS reported
$8.61
revenue$2,965,100,000
- Total revenue $2.97B (+17% YoY); ex-REGEN-COV revenue +25%; GAAP net income $974M, diluted EPS $8.61.
- Non-GAAP net income $1.32B, diluted EPS $11.49 (+16% YoY); free cash flow $1.96B.
- EYLEA U.S. net sales $1.52B (+13%); Dupixent global net sales $1.81B (+43% as recorded by Sanofi).
- R&D guidance raised to $3.27-$3.50B (GAAP), $2.90-$3.10B (non-GAAP); SG&A guidance unchanged.
- REGEN-COV inventory write-offs $58M in COGS; $211M unrealized losses on equity securities; EUA revised.